We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
ERLOTINIB SANDOZ (Sandoz Pty Ltd)
Product name
ERLOTINIB SANDOZ
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
121 working days (255)
Active ingredients
erlotinib hydrochloride
Registration type
New generic medicine
Indication
Non-small cell lung cancer
ERLOTINIB SANDOZ (film coated tablet) is indicated for the first-line treatment of patients with advanced (Stage IIIB) or metastatic (Stage IV) non-small cell lung cancer (NSCLC) with activating EGFR mutations.
ERLOTINIB SANDOZ is indicated for maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutations who have not progressed on first-line chemotherapy.
ERLOTINIB SANDOZ is also indicated for the treatment of patients with locally advanced or metastatic non- small cell lung cancer after failure of prior chemotherapy.
Pancreatic cancer
ERLOTINIB SANDOZ in combination with gemcitabine is indicated for the treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer.